3 results about "Receptor" patented technology

The present invention provides antibodies and antigen-binding fragments (e.g., human E antibodies) that bind specifically to human IL-36 receptor. Methods for treating or preventing diseases mediated by IL36R (e.g., skin or colon inflammatory conditions such as palmo-plantar pustular psoriasis, palmoplantar pustulosis, generalized pustular psoriasis, ulcerative colitis or IBD) using the antibodies and fragments are also provided along with methods of making the antibodies and fragments.

The field of this invention relates to immunohistochemistry (IHC) and in situ hybridization (ISH) for the targeted detection and mapping of biomolecules (e.g., proteins and miRNAs) in tissues or cells for example, for research use and for clinical use such by pathologists (e.g., biomarker analyses of a resected tumor or tumor biopsy). In particular, the use of mass spectrometric imaging (MSI) as a mode to detect and map the biomolecules in tissues or cells for example. More specifically, the field of this invention relates to photocleavable mass-tag reagents which are attached to probes such as antibodies and nucleic acids and used to achieve multiplex immunohistochemistry and in situ hybridization, with MSI as the mode of detection/readout. Probe types other than antibodies and nucleic acids are also covered in the field of invention, including but not limited to carbohydrate-binding proteins (e.g., lectins), receptors and ligands. Finally, the field of the invention also encompasses multi-omic MSI procedures, where MSI of photocleavable mass-tag probes is combined with other modes of MSI, such as direct label-free MSI of endogenous biomolecules from the biospecimen (e.g., tissue), whereby said biomolecules can be intact or digested (e.g., chemically digested or by enzyme).

The invention provides a recombinant cell strain HSCT6-rADHI as well as a construction method and application of the recombinant cell strain HSCT6-rADHI. The recombinant cell strain HSCT6-rADHI is obtained by introducing an ethanol dehydrogenase I gene into a receptor cell strain HSC-T6, and it is found that after high expression of ADHI by HSC, proliferation, invasion and migration capacities of cells can be obviously affected. The recombinant cell strain HSCT6-rADHI can efficiently express ADHI, can be used as a basic test material and a model cell strain, can be used for exploring the occurrence mechanism of hepatic fibrosis, searching for new alleviation measures for hepatic fibrosis, reversing or blocking the hepatic fibrosis process and searching for susceptible factors of hepatic fibrosis, is beneficial to prevention and further targeted therapy of hepatic fibrosis, and has a broad application prospect. The significance is great.